Callan Capital LLC Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Callan Capital LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 27,756 shares of the medical research company’s stock, valued at approximately $2,116,000.

A number of other large investors have also recently bought and sold shares of EW. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $34,000. Operose Advisors LLC boosted its stake in Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares during the last quarter. SRS Capital Advisors Inc. boosted its stake in Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares during the last quarter. NBC Securities Inc. acquired a new position in Edwards Lifesciences during the 3rd quarter valued at about $52,000. Finally, ORG Partners LLC acquired a new position in Edwards Lifesciences during the 3rd quarter valued at about $66,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the completion of the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at $414,596.12. The disclosure for this sale can be found here. Insiders sold a total of 194,004 shares of company stock valued at $17,166,254 over the last three months. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $86.43 on Friday. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $52.02 billion, a PE ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. The firm has a fifty day simple moving average of $90.28 and a two-hundred day simple moving average of $78.85. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. Research analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of several recent analyst reports. Citigroup lifted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Mizuho lifted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Finally, Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday. One analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $93.33.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.